RegulatoryApr 20, 2026, 04:10 PM
BBOT's BBO-11818 Gets FDA Fast Track for Pancreatic Cancer
AI Summary
BridgeBio Oncology Therapeutics (BBOT) announced that the FDA granted Fast Track designation to its pan-KRAS inhibitor, BBO-11818, for advanced KRAS-mutant pancreatic ductal adenocarcinoma. This designation aims to accelerate the development and review process for the drug, which previously showed a confirmed partial response in pancreatic cancer in preliminary data released in January 2026. The company expects updated Phase 1 clinical data in the second half of 2026.
Key Highlights
- FDA granted Fast Track designation to BBO-11818.
- Designation is for advanced KRAS-mutant pancreatic ductal adenocarcinoma.
- BBO-11818 showed confirmed partial response in pancreatic cancer in Jan 2026.
- Updated Phase 1 clinical data expected in H2 2026.
- BBO-11818 is a pan-KRAS inhibitor targeting various KRAS mutations.
Price Impact
More from BBOT